TSHA · Taysha Gene Therapies, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | - | $0 | $1.99M | $2.30M | - | $1.79M | $1.11M | $3.41M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $33.81M | - | $25.75M | $20.14M | $15.56M | - | $14.95M | $15.07M | $20.66M | - |
| SG&A | $9.68M | - | $8.28M | $8.60M | $8.16M | - | $7.90M | $7.34M | $7.08M | - |
| Total Operating Expenses | $43.49M | - | $34.02M | $28.74M | $23.72M | - | $27.69M | $22.41M | $27.74M | - |
| D&A | $295.0K | - | $200.0K | $300.0K | $283.0K | - | $300.0K | $300.0K | $325.0K | - |
| Operating Income | ($43.49M) | - | ($34.02M) | ($26.75M) | ($21.42M) | - | ($25.90M) | ($21.30M) | ($24.33M) | - |
| Interest Expense | $9.0K | - | $15.0K | $17.0K | $29.0K | - | $24.0K | $27.0K | $29.0K | - |
| Income Tax | $0 | - | - | - | $0 | - | - | - | $0 | - |
| Net Income | ($42.41M) | - | ($32.73M) | ($26.88M) | ($21.53M) | - | ($25.52M) | ($20.93M) | ($24.06M) | - |
| EPS - Basic | ($0.12) | - | ($0.09) | ($0.09) | ($0.08) | - | ($0.10) | ($0.09) | ($0.10) | - |
| EPS - Diluted | ($0.12) | - | ($0.09) | ($0.09) | ($0.08) | - | ($0.10) | ($0.09) | ($0.10) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $276.58M | $319.77M | $297.34M | $312.76M | $116.59M | $139.04M | $157.69M | $172.74M | $123.98M | $143.94M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $4.56M | $6.28M | $5.44M | $7.71M | $4.33M | $3.59M | $4.93M | $8.72M | $10.38M | $6.37M |
| Current Assets | $282.25M | $324.65M | $299.95M | $316.26M | $120.71M | $142.13M | $161.56M | $178.47M | $130.60M | $149.87M |
| Total Assets | $300.35M | $343.32M | $316.55M | $333.33M | $138.36M | $160.36M | $180.22M | $200.39M | $153.00M | $172.73M |
| Current Liabilities | $20.10M | $26.55M | $28.63M | $25.35M | $22.56M | $26.23M | $29.34M | $34.18M | $38.64M | $36.76M |
| Long-term Debt | $48.96M | $50.11M | $50.85M | $41.05M | $42.45M | $43.94M | $42.97M | $37.84M | $40.51M | $40.51M |
| Total Liabilities | $88.41M | $96.38M | $97.56M | $84.60M | $83.30M | $88.84M | $91.42M | $91.53M | $99.15M | $97.79M |
| Stockholders' Equity | $211.94M | $246.94M | $218.99M | $248.73M | $55.06M | $71.53M | $88.80M | $108.87M | $53.85M | $74.94M |
| Retained Earnings | ($753.71M) | ($711.30M) | ($683.45M) | ($650.72M) | ($623.83M) | ($602.30M) | ($583.52M) | ($558.00M) | ($537.07M) | ($513.01M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($40.88M) | - | - | - | ($22.02M) | - | - | - | ($19.80M) | - |
| Investing Cash Flow | ($3.02M) | - | - | - | ($371.0K) | - | - | - | ($140.0K) | - |
| Financing Cash Flow | $711.0K | - | - | - | ($52.0K) | - | - | - | ($22.0K) | - |
| CapEx | $378.0K | - | - | - | - | - | - | - | $140.0K | - |
| Free Cash Flow | ($41.26M) | - | - | - | - | - | - | - | ($19.94M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | -1347.1% | -930.5% | - | -1448.4% | -1915.4% | -713.3% | - |
| EBITDA margin | - | - | - | -1332.0% | -918.2% | - | -1431.7% | -1888.4% | -703.8% | - |
| Net margin | - | - | - | -1353.6% | -935.2% | - | -1427.5% | -1882.0% | -705.4% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | -584.5% | - |
| FCF / Net income | 0.97 | - | - | - | - | - | - | - | 0.83 | - |
| R&D / Revenue | - | - | - | 1014.1% | 676.2% | - | 835.9% | 1355.5% | 605.6% | - |
| SG&A / Revenue | - | - | - | 432.9% | 354.4% | - | 441.9% | 659.9% | 207.7% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -14.1% | - | -10.3% | -8.1% | -15.6% | - | -14.2% | -10.4% | -15.7% | - |
| Return on equity | -20.0% | - | -14.9% | -10.8% | -39.1% | - | -28.7% | -19.2% | -44.7% | - |
| Return on invested capital | -13.2% | - | - | - | -17.4% | - | - | - | -20.4% | - |
| Liquidity | ||||||||||
| Current ratio | 14.04 | 12.23 | 10.48 | 12.48 | 5.35 | 5.42 | 5.51 | 5.22 | 3.38 | 4.08 |
| Quick ratio | 14.04 | 12.23 | 10.48 | 12.48 | 5.35 | 5.42 | 5.51 | 5.22 | 3.38 | 4.08 |
| Cash ratio | 13.76 | 12.04 | 10.39 | 12.34 | 5.17 | 5.30 | 5.38 | 5.05 | 3.21 | 3.92 |
| Leverage | ||||||||||
| Debt / Equity | 0.23 | 0.20 | 0.23 | 0.17 | 0.77 | 0.61 | 0.48 | 0.35 | 0.75 | 0.54 |
| Debt / Assets | 0.16 | 0.15 | 0.16 | 0.12 | 0.31 | 0.27 | 0.24 | 0.19 | 0.26 | 0.23 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -4831.8x | - | -2268.3x | -1573.7x | -738.7x | - | -1079.1x | -788.9x | -839.0x | - |
| Equity multiplier | 1.42 | 1.39 | 1.45 | 1.34 | 2.51 | 2.24 | 2.03 | 1.84 | 2.84 | 2.31 |
| Liabilities / Assets | 0.29 | 0.28 | 0.31 | 0.25 | 0.60 | 0.55 | 0.51 | 0.46 | 0.65 | 0.57 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.01 | 0.02 | - | 0.01 | 0.01 | 0.02 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 7.7x | - | 5.3x | 2.8x | 6.8x | - | 6.1x | 4.8x | 12.3x | - |
| P / S | - | - | - | 346.6x | 162.6x | - | 301.1x | 469.0x | 194.6x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -100.0% | - | -100.0% | 78.6% | -32.5% | - | -62.3% | -53.6% | -27.5% | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -103.0% | - | -31.4% | -25.6% | 12.0% | - | -59.4% | 8.9% | -46.9% | - |
| Net income growth (YoY) | -97.0% | - | -28.2% | -28.4% | 10.5% | - | 78.2% | 14.9% | -36.5% | - |
| EPS growth (YoY) | -50.0% | - | 10.0% | 0.0% | 20.0% | - | 89.2% | 76.3% | 92.4% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 17.2% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 284.9% | 245.2% | 146.6% | 128.5% | 2.2% | -4.6% | - | - | - | 7796.4% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Taysha Gene Therapies against the 5 most active filers in the same SIC group.